Exelixis' Cabometyx meets in first-line RCC

Exelixis Inc. (NASDAQ:EXEL) gained $0.44 to $7 on Monday after its Cabometyx cabozantinib met the primary endpoint in the Phase II CABOSUN study evaluating the drug as a first-line therapy for advanced intermediate- or poor-risk renal cell carcinoma.

Cabometyx significantly improved progression-free survival (PFS) vs. Sutent sunitinib, which the company said is standard of care for first-line RCC. Exelixis plans to submit the data for presentation at a future medical conference. ...